China Pharma Holding (STU:XQJ) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:XQJ China Pharma Holding Inc STU:XQJ
26 GF Score
Price €26.80
GF Value €7.07
! 3 Warning Signs
View Full Analysis

What is China Pharma Holding FFO per Share?

FFO per Share only applies to REITs.

STU:XQJ
26GF Score
China Pharma Holding Inc STU:XQJ
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is China Pharma Holding (STU:XQJ) Overvalued in 2026?

Based on GuruFocus' analysis, China Pharma Holding stock appears to be overvalued. The current stock price of €26.80 is trading 279.1% above its estimated GF Value™ of €7.07.

Key valuation signals for STU:XQJ:

  • FFO per Share:
  • GF Value™: €7.07 vs. price of €26.80 (279.1% above fair value)
  • GF Score™: 26/100 with 3 warning signs

No single metric tells the full story. See the STU:XQJ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

China Pharma Holding Business Description

Other Exchanges CPHI:USA
Address No. 17, Jinpan Road, Second Floor, Jiahai Building, Hainan Province, Haikou, CHN, 570216
China Pharma Holding Inc is a drug manufacturing company. It is mainly engaged in the development, manufacture, and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the People's Republic of China. The company mainly manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The product line of the company includes cefaclor dispersible tablets, clarithromycin granules, roxithromycin dispersible tablets, andrographolide tablets, ozagrel sodium for injection, gastrodin injection, and others.
26GF Score

Get the complete analysis for STU:XQJ

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€26.80
Price
€7.07
GF Value